Instalab
logoInstalab

Tetracycline Resistance

Stool Test
Find out whether the bacteria in your gut can shrug off one of the most widely used antibiotic families.
4.9 (2,995 reviews)
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Self-collect at home
Easy self-collection kit
Get results
Explained with clear next steps, no medical jargon

Should you take a Tetracycline Resistance test?

This test is most useful if any of these apply to you.

Using Doxy-PEP
You take doxycycline after sex to prevent STIs. This shows whether the strategy is shifting your gut toward tetracycline resistance.
Recently on a Long Antibiotic Course
You finished doxycycline, minocycline, or tetracycline for acne, rosacea, or an infection. See what it left behind in your gut.
Living With Recurrent Infections
You keep needing antibiotics for the same kind of infection. Knowing what your gut harbors helps guide which drugs are still worth trying.
Healthy but Want a Baseline
You're well now, but you want to know your resistance starting point so future shifts are easier to spot when you actually need an antibiotic.

About Tetracycline Resistance

If a doctor prescribes you doxycycline for an infection or as ongoing prophylaxis, the drug only works if the bacteria it targets cannot defend themselves against it. Tetracycline resistance is the property that determines whether those bacteria win or lose that fight.

This test looks for tetracycline resistance genes carried by the bacteria living in your gut. The result reflects how much of the tetracycline-class antibiotic family (doxycycline, minocycline, tetracycline, and the newer tigecycline and omadacycline) those bacteria are equipped to resist, both for current treatment decisions and for future ones.

What This Test Actually Measures

Tetracycline resistance is not a human hormone or metabolite. It is a set of bacterial genes and proteins that allow microbes in your stool to survive exposure to tetracycline-class drugs. The genes (called tet genes) are typically grouped by the strategy they encode: efflux pumps that push the drug out of the bacterial cell, ribosomal protection proteins that shield the bacterial machinery the drug normally jams, and enzymes that chemically inactivate the drug itself.

These genes are most often carried on small pieces of mobile DNA (plasmids and transposons) that bacteria can hand off to one another, even across species. That is why a resistance gene that started in a foodborne bug can end up in a harmless gut bacterium, and from there potentially in a future pathogen.

Why Your Gut Is the Right Place to Look

Your gut is one of the largest reservoirs of antibiotic resistance genes in the body. A metagenomic study of 246 healthy individuals found that tetracycline resistance genes were the most abundant antibiotic resistance genes in human gut microbiota and that they accumulated and became more complex with age.

The genes carried by your gut bacteria today shape what happens when you next take a tetracycline. They also influence what happens to people around you, since these genes can spread through close contact and shared environments.

How This Affects Real Treatment Decisions

Tetracycline resistance is widespread enough across common pathogens that it routinely changes which drugs actually work. The numbers vary a lot depending on what the bacteria are and where they live.

Where Resistance Was MeasuredWhat Was FoundSource
Group B Streptococcus in pregnant womenAbout 94% of isolates were resistant to tetracycline; most carried tet(M) and/or tet(O)Zakerifar et al., 2023
Clinical Enterococcus faecalis (global)About 67% of isolates were resistant to tetracycline, among the highest of all drugs testedGuan et al., 2024
Salmonella from poultry and porkAbout 71% of isolates were resistant, dominated by tet(A) and tet(B) on plasmidsPavelquesi et al., 2021

What this means for you: tetracycline-class drugs are still go-to options for acne, certain respiratory infections, tick-borne illnesses, sexually transmitted infections, and as part of doxy-PEP (post-exposure prophylaxis). When resistance is high in the bacteria most likely to cause your infection, the antibiotic may simply not work, and a backup option will be needed.

Newer Tetracyclines Are Not a Free Pass

Third-generation tetracyclines (tigecycline, eravacycline, and omadacycline) were specifically designed to bypass the older resistance tricks like efflux pumps and ribosomal protection. They are often used as last-line drugs for serious multidrug-resistant infections.

But resistance is already catching up. The Tet(X) family of enzymes can chemically inactivate even these newer drugs, and overactive multidrug efflux pumps and mutations in bacterial ribosomes are also eroding their effectiveness. Tracking what your gut harbors gives a window into how prepared your microbiome is to defeat both old and new tetracyclines.

What Doxycycline Use Does to Your Resistance Levels

The most direct way to push tetracycline resistance up is to take a tetracycline. In a randomized trial of 220 men who have sex with men and transgender women using doxycycline 200 mg after condomless sex (a regimen called doxy-PEP), the share of the gut resistome made up of tetracycline resistance genes rose from 46% to 51% over six months, and actively expressed tetracycline resistance genes climbed from 4% to 15% over the same period.

A separate systematic review of randomized trials found that 2 to 18 weeks of oral tetracyclines (doxycycline, tetracycline, oxytetracycline, or minocycline) increased tetracycline-resistant bacteria in subgingival, gastrointestinal, and upper respiratory tract flora. The effect on resistance to other antibiotic classes was generally small or transient. The change is real, not a measurement artifact, and can persist for weeks after the drug is stopped.

Doxy-PEP and Sexually Transmitted Infections

Doxy-PEP is being used to prevent bacterial sexually transmitted infections, and it works partly because doxycycline can clear susceptible bugs before they cause an infection. The catch is that it only works for bacteria that are still susceptible. A systematic review found median tetracycline resistance of about 54% in Neisseria gonorrhoeae globally, with rates exceeding 80% in some regions and rising over time.

In a substudy of the ANRS 174 DOXYVAC randomized trial of 545 men, doxy-PEP use was linked to higher rates of high-level tetracycline resistance and reduced susceptibility to cefixime in gonorrhea isolates. If you use doxy-PEP, knowing your gut resistome gives you and your clinician a way to track whether the strategy is selecting for harder-to-treat bacteria over time.

Reference Ranges and Why They Are Different Here

This is a Tier 3 research-grade marker. There are no standardized clinical cutpoints that say a given level of tetracycline resistance genes is normal or abnormal in a healthy person. The thresholds that exist in microbiology apply to bacterial isolates grown in the lab, not to the mixed gene pool found in your gut.

For context, the standard microbiology cutpoints used to classify a bacterial strain as resistant come from EUCAST and CLSI guidelines and US national surveillance. They look like this:

SettingResistance DefinitionSource
Neisseria gonorrhoeae (global, EUCAST and CLSI)Minimum inhibitory concentration above 1 milligram per literDo et al., 2025
Neisseria gonorrhoeae (US national surveillance)Resistant at 2 micrograms per milliliter or higher; high-level resistant at 16 or higherWondmeneh et al., 2025
Tetracycline-class drugs (research models)To suppress new resistance from emerging, drug exposure should keep AUC/MIC at 50 or higherSumi et al., 2019

These ranges classify single bacterial isolates and do not translate into a personal target for your gut resistome. Cutpoints do not vary by age, sex, or ethnicity. Your own result is most useful when compared to your previous results from the same lab using the same method, since assays for resistance gene detection are not yet standardized across providers.

Why One Reading Is Not Enough

The gut resistome is a moving target. It shifts when you take antibiotics, change your diet, get an infection, or simply age. A single snapshot tells you what is happening today, but the more useful information is the direction of travel.

Get a baseline now. If you start a course of doxycycline, doxy-PEP, or any other tetracycline, retest at 3 to 6 months to see whether your resistance gene load is climbing. If you make a deliberate change like a diet shift, a microbiome restoration program, or a course of probiotics, retest at 3 to 6 months to see whether the change moved the needle. After that, annual monitoring is reasonable for anyone using tetracyclines repeatedly or working actively to reduce their resistome.

What an Elevated Result Should Make You Do

A high tetracycline resistance signal is not a diagnosis. It is a flag that the bacteria in your gut are well-equipped to defeat this antibiotic class, which matters most when you actually need one. The right next steps depend on context.

  • If you are using doxy-PEP or recurrent doxycycline: discuss with your clinician whether the prophylactic benefit still outweighs the resistance trade-off, and consider periodic STI cultures with susceptibility testing rather than empiric treatment.
  • If you have a current bacterial infection: make sure the treating clinician orders culture and susceptibility testing on the actual pathogen rather than picking a tetracycline empirically.
  • If you have no immediate infection but a high resistome load: focus on the modifiable inputs (avoiding unnecessary antibiotic use, gut-targeted dietary changes) and retest in 3 to 6 months to see if the trend reverses.
  • If you have recurrent infections involving multidrug-resistant organisms: an infectious disease specialist can interpret the resistome alongside cultures and decide whether last-line tetracyclines like tigecycline are still likely to work.

When Results Can Be Misleading

A single result can be distorted by recent events. Consider these factors before drawing conclusions:

  • Recent antibiotic use: any antibiotic course, not just a tetracycline, can transiently reshape the gut microbiome and the resistome for weeks. If you can, wait at least 4 to 6 weeks after finishing antibiotics before testing.
  • Recent travel or gastrointestinal illness: picking up new bacteria from food, water, or unfamiliar environments can temporarily change which resistance genes are present.
  • Probiotics taken close to testing: probiotic strains can carry their own resistance genes, and a fresh dose may add genes that are not really part of your stable microbiome.
  • Lab-to-lab variation: there is no standardized assay for gut resistance genes, so results from different labs may not be directly comparable. Stick with one lab for serial tracking.

None of these factors mean the test is wrong, only that a single reading taken at a noisy moment may not represent your usual state. The trend across multiple readings is more informative than any one number.

What Moves This Biomarker

Evidence-backed interventions that affect your Tetracycline Resistance level

Increase
Take doxycycline post-exposure prophylaxis (200 mg after condomless sex)
Doxy-PEP raises the share of your gut bacteria armed against tetracyclines, which can blunt how well doxycycline works for you in the future. In a randomized trial of 220 men who have sex with men and transgender women, six months of doxy-PEP raised tetracycline resistance genes from 46% to 51% of the gut resistome and actively expressed tetracycline resistance genes from 4% to 15%. The same study found a median of 42 doses over six months produced this shift without changing overall microbiome diversity, meaning the resistance signal is real selection, not collateral damage.
MedicationStrong Evidence
Decrease
Receive microbiota restoration therapy (RBX2660) after recurrent C. difficile infection
Restoring the microbiome after antibiotics reduces the overall pool of resistance genes, including tetracycline ones, and helps clear multidrug-resistant gut colonizers. In an open-label trial of 29 adults with recurrent C. difficile infection, RBX2660 produced a substantial drop in antibiotic-resistant Enterobacteriaceae over two months, with fecal resistance gene carriage declining in proportion to how well the donor microbiome engrafted. A separate placebo-controlled phase 2b trial showed faster and more complete reduction of total resistance gene abundance through 60 days versus placebo.
MedicationStrong Evidence
Decrease
Follow a gut-microbiota-targeted diet shifting fermentation from protein toward fiber and complex carbohydrates
A targeted dietary change can broadly shrink the resistance gene pool in your gut, including tetracycline efflux pumps. In obese children, a gut-targeted diet reduced 33 of 36 changed resistance gene types, with the summed abundance of those genes dropping roughly 44% (from 1364.2 to 761.6 arbitrary units per individual). Tetracycline efflux pumps Tet40 and TetC and multidrug efflux systems decreased significantly, while one tetracycline gene (TetL) rose modestly.
DietStrong Evidence
Increase
Take a 2 to 18 week course of oral tetracycline-class antibiotics (doxycycline, minocycline, tetracycline, or oxytetracycline)
Any sustained tetracycline course pushes up the resistant share of bacteria in your mouth, gut, and upper airway, sometimes for weeks after you stop. A systematic review of randomized trials found that 2 to 18 weeks of oral tetracyclines increased tetracycline-resistant bacteria in subgingival, gastrointestinal, and upper respiratory flora, with effects on other antibiotic classes generally small or transient. This means a course taken for acne, rosacea, periodontitis, or a respiratory infection can leave behind a more resistant microbiome that complicates future antibiotic choices.
MedicationModerate Evidence
Decrease
Take Bifidobacterium-based probiotic supplementation in early life
Targeted probiotic use can reduce overall resistance gene burden when the gut microbiome is being established, though the effect is strain- and host-specific. In 34 very-low-birth-weight preterm infants, Bifidobacterium-based probiotic supplementation significantly reduced overall antibiotic resistance gene prevalence and multidrug-resistant pathogen load while restoring a more typical early-life microbiota. A meta-analysis of 29 randomized trials including 2,871 participants also found probiotics reduced persistence of pathogenic bacteria (22% versus 30.8%; pooled odds ratio 0.59, 95% confidence interval 0.43 to 0.81), suggesting better colonization resistance.
SupplementModerate Evidence

Frequently Asked Questions

References

19 studies
  1. Chu VT, Glascock AL, Donnell D, Grabow C, Brown CE, Ward R, Love C, Kalantar KL, Cohen SE, Cannon CA, Woodworth M, Kelley CF, Celum C, Luetkemeyer a, Langelier CNature Medicine2024
  2. Wu L, Xie X, Li Y, Liang T, Zhong H, Ma J, Yang L, Yang J, Li L, Xi Y, Li H, Zhang J, Chen X, Ding Y, Wu QAntibiotics2021
  3. Wondmeneh S, Learner ER, Schmerer M, Harvey a, Mauk K, Papp J, Quilter LAS, St Cyr SSSexually Transmitted Diseases2025